{
    "clinical_study": {
        "@rank": "131021", 
        "arm_group": [
            {
                "arm_group_label": "Xinfeng capsule & placebo", 
                "arm_group_type": "Experimental", 
                "description": "Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months\nplacebo(for leflunomide): 10 mg each time, 1 time a day, Oral,for3 months"
            }, 
            {
                "arm_group_label": "leflunomide  & placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "leflunomide :10mg each time, one time a day, by mouth,for 3 months\nplacebo(for xinfeng capsule):Three each time, 3 times a day, Oral,for3 months"
            }
        ], 
        "brief_summary": {
            "textblock": "Bi Syndrome is one of  Traditional Chinese Medicine\uff08TCM\uff09name, It means an obstruction in\n      Chinese,and it refers the syndrome characterized by the obstruction of qi and blood in the\n      meridians due to the invasion of external pathogenic wind,cold and dampness, manifested as\n      soreness, pain, numb,etc. Bi Syndrome  contains Rheumatoid arthritis(RA). RA is a chronic\n      disease affecting more than 20 million people in the world.It is one of the most common\n      forms of autoimmune disease. Xin'an Medicine is one of Traditional Chinese Medicine which\n      originated from AnHui. Xinfeng Capsule developed according to the Xin'an medicine theory\n      ,and it has long been adopted for treatment of rheumatoid arthritis (RA). The study is aimed\n      to evaluate the effectiveness and safety of Xinfeng Capsule in the treatment of RA."
        }, 
        "brief_title": "A Clinical Study of Xin'an Medicine in the Treatment of Bi Syndrome", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of RA, classified by American Rheumatism Association 1987 revised criteria.\n\n          -  According with the Zheng diagnosis of Traditional Chinese Medicine.\n\n          -  age from 18 to 65 years.\n\n          -  For patients currently receiving non-steroidal anti-inflammatory drugs (NSAIDs):\n             Treatment at a stable dose during last 4 weeks prior to screening\uff0cor Patients do not\n             take NSAIDs at least 1 weeks prior to screening.\n\n          -  Patients not taking DMARDs at least 4 weeks prior to screening.\n\n          -  Patients taking corticosteroids (\u226415mg prednisone or Equivalent) \u22654 weeks before\n             entering the trial.\n\n          -  Patients agree to participate in this study and sign the informed consent form.\n\n        Exclusion Criteria:\n\n          -  Patients have received intra-articular or systemic corticosteroid injection within 4\n             weeks of screening.\n\n          -  Patients have high disease activity (DAS28-3 scores> 5.1).\n\n          -  Patients have diagnosed any other chronic inflammatory disease or connective tissue\n             disease like sicca syndrome\uff08SS\uff09, systemic lupus erythematosus (SLE)etc;\n\n          -  Patients with sever diseases in Cardiovascular, brain, lung, liver, kidney and\n             hematopoietic system ;\n\n          -  Patients who are pregnant or nursing mothers or Psychiatric patients.\n\n          -  Patients with active gastroduodenal ulcer or gastritis which caused by long-term use\n             of NSAIDs;\n\n          -  The patient who has known hypersensitivity to trial medicine .\n\n          -  Patients have participated in other clinical trials within 4 weeks of screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "304", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01774877", 
            "org_study_id": "2012BAI26B02"
        }, 
        "intervention": [
            {
                "arm_group_label": "Xinfeng capsule & placebo", 
                "description": "Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months; placebo(for leflunomide):10mg each time, 1 time a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and  NSAIDs  that they were receiving prior to study entry", 
                "intervention_name": "Xinfeng capsule", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "leflunomide  & placebo", 
                "description": "leflunomide :10mg each time, one time a day, Oral,for 3 months; placebo(for xinfeng capsule):Three each time, 3 times a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and  NSAIDs  that they were receiving prior to study entry", 
                "intervention_name": "leflunomide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Leflunomide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "xinfeng capsule;", 
            "rheumatoid arthritis (RA);", 
            "randomized;", 
            "double-blind;"
        ], 
        "lastchanged_date": "July 30, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Li Zhijun", 
                    "phone": "86-0552-3065724"
                }, 
                "facility": {
                    "address": {
                        "city": "Bengbu", 
                        "country": "China", 
                        "state": "Anhui", 
                        "zip": "233004"
                    }, 
                    "name": "The first affiliated hospital of bengbu medical college"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Xu Jianhua", 
                    "phone": "86-0551-62922016"
                }, 
                "facility": {
                    "address": {
                        "city": "Hefei", 
                        "country": "China", 
                        "state": "Anhui", 
                        "zip": "230031"
                    }, 
                    "name": "The first affiliated hospital of anhui medical university"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "li yan", 
                    "phone": "86-0553-5738279"
                }, 
                "facility": {
                    "address": {
                        "city": "Wuhu", 
                        "country": "China", 
                        "state": "Anhui", 
                        "zip": "241001"
                    }, 
                    "name": "Yijishan Hospital of Wannan Medical College"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of Xinfeng Capsule in the Treatment of Rheumatoid Arthritis (RA):A Randomized, Double-blind, Double-dummy, Multi-center Trial", 
        "overall_contact": {
            "email": "liujianahzy@yahoo.com.cn", 
            "last_name": "Liu Jian, Doctor", 
            "phone": "86-055162838582"
        }, 
        "overall_official": {
            "affiliation": "The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine", 
            "last_name": "liu jiu, doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Science and Technology", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "ACR20 used for evaluating the efficacy of  rheumatoid arthritis (RA).", 
            "measure": "ACR20  (American College of Rheumatology (ACR) criteria of 20% improvement in symptoms )", 
            "safety_issue": "No", 
            "time_frame": "baseline,week4,week8,week12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01774877"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine", 
            "investigator_full_name": "Liu Jian", 
            "investigator_title": "professor\uff0cChief Physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "ACR50 used for evaluating the efficacy of rheumatoid arthritis (RA).", 
                "measure": "ACR50 (American College of Rheumatology (ACR) criteria of 50% improvement in symptoms )", 
                "safety_issue": "No", 
                "time_frame": "baseline,week4,week8\uff0cweek12"
            }, 
            {
                "description": "ACR50 used for evaluating the efficacy of rheumatoid arthritis (RA).", 
                "measure": "ACR70 (American College of Rheumatology (ACR) criteria of 70% improvement in symptoms )", 
                "safety_issue": "No", 
                "time_frame": "baseline,week4,week8\uff0cweek12"
            }, 
            {
                "measure": "Patterns based on Chinese medicine(CM)symptoms", 
                "safety_issue": "No", 
                "time_frame": "baseline,week4,week8\uff0cweek12"
            }, 
            {
                "measure": "Disease Activity Scale (DAS)28", 
                "safety_issue": "No", 
                "time_frame": "baseline,week4,week8, week12"
            }, 
            {
                "description": "Rheumatoid arthritis (RA) biomarkers,including rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) ,anti-cyclic citrullinated peptide (anti-CCP) antibodies, IgG\u3001IgA\u3001IgM, d-dimer, the coagulation function tests", 
                "measure": "Rheumatoid arthritis (RA) biomarkers", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, week12"
            }, 
            {
                "description": "Life Quality Assessment,including Health Assessment Questionnaire (HAQ), Self-rating depression scale(SDS), Self-rating anxiety scale(SAS),quality of life Questionnaire with rheumatoid arthritis.", 
                "measure": "Life Quality Assessment", 
                "safety_issue": "No", 
                "time_frame": "baseline,week12"
            }, 
            {
                "measure": "x-rays of the hands and wrists", 
                "safety_issue": "No", 
                "time_frame": "baseline,week12"
            }
        ], 
        "source": "The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine", 
        "sponsors": {
            "collaborator": {
                "agency": "Ministry of Science and Technology of the People\u00b4s Republic of China", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}